ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

Nalbuphine HCl Injection
Narcotic analgesics
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

Nalbuphine HCl Injection Rx

Generic Name and Formulations:
Nalbuphine HCl 10mg/mL, 20mg/mL; SC, IM or IV inj; vials; amps.

Company:
Various generic manufacturers

Therapeutic Use:

Indications for Nalbuphine HCl Injection:

Pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Pre-op and post-op pain. Pain during labor and delivery. Supplement to balanced anesthesia.

Adult:

Pain: Individualize. Initially 10mg per 70kg SC, IM, or IV every 3–6hrs as needed. Non-tolerant: max single dose of 20mg; max total daily dose of 160mg. Anesthesia (induction): usual range: 0.3–3mg/kg IV over 10–15mins; (maintenance): usual range: 0.25–0.5mg/kg in single IV administrations as needed.

Children:

<18yrs: not established.

Contraindications:

Significant respiratory depression. Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment. Known or suspected GI obstruction, including paralytic ileus.

Warnings/Precautions:

Life-threatening respiratory depression; monitor within first 24–72hrs of initiating therapy and following dose increases. COPD, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression; monitor and consider non-opioid analgesics. Abuse potential (monitor). Adrenal insufficiency. Head injury. Increased intracranial pressure, brain tumors; monitor. Seizure disorders. CNS depression. Impaired consciousness, coma, shock; avoid. Biliary tract disease. Acute pancreatitis. MI with nausea/vomiting. Drug abusers. Renal or hepatic impairment. Reevaluate periodically. Avoid abrupt cessation. Elderly. Cachectic. Debilitated. Pregnancy; avoid; potential neonatal opioid withdrawal syndrome during prolonged use. Labor & delivery. Nursing mothers.

Interactions:

Increased risk of hypotension, respiratory depression, sedation with benzodiazepines or other CNS depressants (eg, non-benzodiazepine sedatives/hypnotics, anxiolytics, general anesthetics, phenothiazines, tranquilizers, muscle relaxants, antipsychotics, alcohol, other opioids); reserve concomitant use in those for whom alternative options are inadequate; limit dosages/durations to minimum required; monitor. During or within 14 days of MAOIs: not recommended. Avoid concomitant full opioid agonist analgesic. Risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, 5-HT3 antagonists, mirtazapine, trazodone, tramadol, MAOIs, linezolid, IV methylene blue); monitor and discontinue if suspected. May antagonize diuretics; monitor. Paralytic ileus may occur with anticholinergics.

Pharmacological Class:

Opioid (agonist-antagonist).

Adverse Reactions:

Sedation, sweaty/clammy, nausea/vomiting, dizziness/vertigo, dry mouth, headache, allergic reactions; respiratory depression, severe hypotension, syncope.

Note:

Formerly known under the brand name Nubain.

How Supplied:

Contact supplier.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs